

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 2, 2012
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 2, 2012.

2. Welcome

Deborah Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Ms. Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Edward Behling, MD
Sara Lindsey, MD
Tan Platt, MD
Deborah Tapley, R.Ph.

Jim Lindsay, MD
Thomas Phillips, R.Ph.
Gregory Browning, MD

M. Narasimhan, MD, DFAPA
Kelly Jones, MD
George Vess, PharmD

SC DHHS Staff:

James M Assey, R.Ph.
Marion Burton, MD
Jim Bradford, MD
Vicki Johnson
Will Feagin

Magellan Medicaid Administration:

Mary Roberts, R.Ph.
Lisa Correll, PharmD

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 1, 2012.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Shire USA, Inc.	Patrick Hunt, PharmD	Vyvanse®
Eli Lilly & Company	Briana Buckley, PharmD	Zyprexa Relprevv®
C. Amidon, PharmD	Kowa Pharmaceuticals America	Livalo®
Steven Earle, Ph.D.	AstraZeneca	Crestor®
Vicki Star, MD	Merck	Zetia®
Brad Burmeister	Daiichi Sankyo, Inc.	Welchol®
K. Linsky, PharmD	GlaxoSmithKline	Lovaza® Ventolin® HFA
Chris Picknell	Teva Respiratory, LLC	ProAir® HFA
S. Hernandez, PharmD	Novartis Pharmaceuticals	Arcapta® Neohaler
Jessica McKeon, MD	Novo Nordisk, Inc	Norditropin Flexpro®
Whitney Brown, MD	USC School of Medicine	Genotropin®
Tarina Mendes, MD	Seneca Pediatric Endocrinology	General Testimony

C. Drug Classes for Review

Mary Roberts led the discussion for the following drug classes:

- Anticonvulsants, Rectal Preparations
- Atypical Antipsychotics, Long Acting Injectables
- Stimulants for ADHD
- Lipotropics, Statins
- Lipotropics, Cholesterol Absorption Inhibitors
- Lipotropics, Bile Acid Sequestering Resins
- Lipotropics, Fibric Acid Derivatives
- Short Acting Beta Agonist Inhalers
- Long Acting Beta Agonist Inhalers
- Pancreatic Enzymes
- Proton Pump Inhibitors
- Growth Hormones

The chart below represents the recommendations from the P & T Committee:

ANTICONVULSANTS, RECTAL PREPARATIONS	
Preferred	Non-Preferred
Diastat	Diazepam Rectal

ATYPICAL ANTIPSYCHOTICS, LONG ACTING INJECTABLES	
Preferred	Non-Preferred
Invega Sustenna Risperdal Consta	Zyprexa RelPrevv

STIMULANTS FOR ADHD	
Preferred	Non-Preferred
Amphetamine Salt Combo Adderall XR Concerta Dexmethylphenidate Dextroamphetamine Tablet Destroamphetamine Cap ER Focalin XR Intuniv Metadate CD Methylphenidate Methylphenidate ER Ritalin LA Strattera Vyvanse	Amphetamine Salt Combo ER Daytrana Desoxyn Dexedrine Spansule Focalin Kapvay Methamphetamine Methylphenidate ER (Generic Concerta) Methylphenidate ER (Generic Ritalin LA) Methylin Nuvigil Procentra Provigil Ritalin Ritalin SR

LIPOTROPICS, STATINS	
Preferred	Non-Preferred
Atorvastatin Lescol Lescol XL Lovastatin Pravastatin Simcor Simvastatin	Advicor Altoprev Amlodipine-Atorvastatin Caduet Crestor† Lipitor Livalo Mevacor Pravacol Vytorin Zocor <i>†Those patients already on Crestor® will be grandfathered.</i>

LIPOTROPICS, CHOLESTEROL ABSORPTION INHIBITORS	
Preferred	Non-Preferred
	Zetia ‡ ‡No PA required for Zetia® if statin or fenofibrate within 90 days in patient history

LIPOTROPICS, BILE ACID SEQUESTERING RESINS	
Preferred	Non-Preferred
Cholestyramine Cholestyramine Light Colestipol Tablet	Colestid Colestipol Granules Questran Questran Light Welchol‡ ‡No PA required for Welchol® if concurrent statin or intolerance to statin within 90 days in patient history

LIPOTROPICS, FIBRIC ACID DERIVATIVES	
Preferred	Non-Preferred
Gemfibrozil Tricor Trilipix	Antara Fenofibrate Fenofibric Acid Fibracor Lipofen Lopid Lovaza‡ Triglide ‡No PA required for Lovaza® if intolerance of Fenofibrate, Gemfibrozil or Niacin within 90 days in patient history.

LONG ACTING BETA AGONIST INHALERS	
Preferred	Non-Preferred
Foradil Serevent	Arcapta

PANCREATIC ENZYMES	
Preferred	Non-Preferred
Creon Pancrelipase Zenpep	Pancreaze

PROTON PUMP INHIBITORS	
Preferred	Non-Preferred
Pantoprazole Omeprazole OTC Omeprazole RX	Aciphex Dexilant Lansoprazole Nexium† Prevacid Prilosec OTC Protonix Zegerid OTC †Those patients already on Nexium® will be grandfathered.

GROWTH HORMONES	
Preferred	Non-Preferred
Norditropin Nutropin	Genotropin† Humatrope Omnitrope Saizen Serostim Tev-Tropin Zorbtive †Those patients already on Genotropin® will be grandfathered.

5. **Old Business**

The Committee approved minutes from the May 4, 2011 meeting which were revised to include Geodon as “preferred”.

6. **New Business**

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Anticonvulsants, Rectal Preparations
- Atypical Antipsychotics, Long Acting Injectables
- Stimulants for ADHD
- Lipotropics, Statins
- Lipotropics, Cholesterol Absorption Inhibitors
- Lipotropics, Bile Acid Sequestering Resins
- Lipotropics, Fibric Acid Derivatives
- Long Acting Beta Agonist Inhalers

Pancreatic Enzymes
Proton Pump Inhibitors
Growth Hormones

The Committee deferred review of the following class until August 2012:
Short Acting Beta Agonist Inhalers

8. Closing Comments

The next meeting will be held on Wednesday, August 1, 2012, at 4:00 p.m.

9. Adjournment

The meeting adjourned at 6:35 p.m.